Slingshot members are tracking this event:
Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer
Slingshot Insights Explained
Jun 27, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Breakthrough Therapy Designation, Phase 2 Study Ca209-275, Bladder Cancer, Urothelial Cancer